We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Cofactor Genomics Acquires Narus Biotechnologies
News

Cofactor Genomics Acquires Narus Biotechnologies

Cofactor Genomics Acquires Narus Biotechnologies
News

Cofactor Genomics Acquires Narus Biotechnologies

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Cofactor Genomics Acquires Narus Biotechnologies"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

This acquisition advances Cofactor’s expansion into RNA-based diagnostics and further solidifies their plans for the development and delivery of RNA-based tests for cancer and neurodegenerative disease. Cofactor’s initial products are aimed at the pre-clinical and clinical segments of the pharmaceutical market, where Cofactor has nine of the world’s largest pharmaceutical companies under contract for studies using RNA to understand disease. 

“In addition to acquiring Narus’ assets related to RNA biomarkers, we gain an extremely talented team that is already helping to accelerate Cofactor’s RNA-based diagnostic roadmap,” stated Dr. Jarret Glasscock, Cofactor’s CEO. “This acquisition brings two major changes to Cofactor: it establishes Cofactor’s San Francisco presence and secures the resources necessary to change the face of medicine by using RNA to detect disease and monitor treatment progression.”

“There is a multitude of diseases where a tissue biopsy is just not feasible and current techniques like cell-free DNA are noninformative. We’re excited to integrate the techniques we’ve developed using cell-free RNA with the proven track record of an institution like Cofactor,” stated Raman Talwar, Narus co-founder and Cofactor’s newly appointed Director of Diagnostic Development.

Advertisement